ATE494548T1 - Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase - Google Patents

Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase

Info

Publication number
ATE494548T1
ATE494548T1 AT06784518T AT06784518T ATE494548T1 AT E494548 T1 ATE494548 T1 AT E494548T1 AT 06784518 T AT06784518 T AT 06784518T AT 06784518 T AT06784518 T AT 06784518T AT E494548 T1 ATE494548 T1 AT E494548T1
Authority
AT
Austria
Prior art keywords
ubiquitin
complex
methods
ligase
characterization
Prior art date
Application number
AT06784518T
Other languages
English (en)
Inventor
Hengbin Wang
Ru Cao
Yi Zhang
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE494548T1 publication Critical patent/ATE494548T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
AT06784518T 2005-06-02 2006-06-01 Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase ATE494548T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68676905P 2005-06-02 2005-06-02
US75056405P 2005-12-15 2005-12-15
PCT/US2006/021159 WO2006130720A2 (en) 2005-06-02 2006-06-01 Purification, characterization and reconstitution of a ubiquitin e3 ligase

Publications (1)

Publication Number Publication Date
ATE494548T1 true ATE494548T1 (de) 2011-01-15

Family

ID=37482290

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06784518T ATE494548T1 (de) 2005-06-02 2006-06-01 Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase

Country Status (5)

Country Link
US (1) US7923219B2 (de)
EP (1) EP1891434B1 (de)
AT (1) ATE494548T1 (de)
DE (1) DE602006019423D1 (de)
WO (1) WO2006130720A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
ES2617379T3 (es) 2012-04-13 2017-06-16 Epizyme, Inc. Forma de sal de un inhibidor de histona metiltransferasa EZH2 humana
BR112015008480A2 (pt) 2012-10-15 2017-07-04 Epizyme Inc compostos de benzeno substituído
CA2911195A1 (en) * 2013-04-05 2014-10-09 Mo Bio Laboratories, Inc. Kits and methods for isolating protein from biological and environmental samples
WO2014179755A2 (en) * 2013-05-02 2014-11-06 E3X Bio Method for identifying modulators of ubiquitin ligases
PE20161273A1 (es) 2013-10-16 2016-12-18 Epizyme Inc Forma salina de hidrocloruro para la inhibicion de ezh2
WO2017040992A1 (en) 2015-09-04 2017-03-09 Mo Bio Laboratories, Inc. Methods for co-isolation of nucelic acids and proteins
WO2018132825A2 (en) * 2017-01-16 2018-07-19 Memorial Sloan Kettering Cancer Center Treatment of sarcoma
CN112313344A (zh) 2018-04-24 2021-02-02 凯杰科技有限公司 从复杂样品中分离核酸并去除抑制剂
EP3989949A4 (de) * 2019-06-27 2023-07-12 Board of Regents, The University of Texas System Hemmung von prc1 zur behandlung von krebs
KR102288716B1 (ko) * 2019-10-30 2021-08-12 경상남도 항비만 효능을 갖는 펩타이드 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740495B1 (en) * 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
US6919184B2 (en) * 2000-04-03 2005-07-19 Rigel Pharmaceuticals, Inc. Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
AU2003290538A1 (en) * 2002-10-30 2004-06-07 Meso Scale Technologies, Llc Substrates of n-end rule ubiquitylation and methods for measuring the ubiquitylation of these substrates
GB0228900D0 (en) * 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
EP1651595A2 (de) * 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitinligaseinhibitoren

Also Published As

Publication number Publication date
US20080248458A1 (en) 2008-10-09
US7923219B2 (en) 2011-04-12
EP1891434A2 (de) 2008-02-27
EP1891434B1 (de) 2011-01-05
DE602006019423D1 (de) 2011-02-17
WO2006130720A2 (en) 2006-12-07
EP1891434A4 (de) 2008-08-27
WO2006130720A3 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
ATE449168T1 (de) Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür
DE602006019423D1 (de) Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase
ATE404574T1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
WO2008115518A3 (en) Biomarkers of sirtuin activity and methods of use thereof
WO2003089904A3 (en) Aib1 as a prognostic marker and predictor of resistance to encocrine therapy
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer
WO2003079020A3 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
WO2004037159A3 (en) Compounds, compositions and methods for modulating fat metabolism
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
DE602006002809D1 (de) Verfahren zur erkennung eines ovarialkarzinoms
EP2230319A3 (de) Genexpressionsmarker für Brustkrebsprognose
WO2007149482A3 (en) Xanthohumol based protein kinase modulation cancer treatment
NO20082386L (no) Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
ATE328112T1 (de) Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon
WO2004074324A3 (en) Modulation of the poliovirus receptor function
BR0315689A (pt) Alvo para terapia de dano cognitivo
BRPI0515319A (pt) análogos de quinolona
WO2007064776A3 (en) Markers for breast cancer
ATE428417T1 (de) Derivate von piperidinylalkylcarbamaten, herstellungsverfahren davon und verwendung derselben als faah-enzym-inhibitoren
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2005110479A3 (en) Treatments for pancreatic cancer
ATE426039T1 (de) Verfahren fur den nachweis von streptococcus agalactiae mittels alpha-glucosidase-aktivitat
WO2006078422A3 (en) Methods for modulating tumor growth and metastasis
DE502005007105D1 (de) 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü-pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties